Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Hexima Limited
  6. News
  7. Summary
    HXL   AU0000111932

HEXIMA LIMITED

(HXL)
  Report
Delayed Australian Stock Exchange  -  12:10:44 2023-02-02 am EST
0.0170 AUD   -5.56%
01/30Hexima Limited Declares Voting Results
CI
01/03Arovella Therapeutics Appoints COO
MT
2022Hexima Acting CEO to Step Down
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Hexima : CEO's Presentation

12/01/2021 | 05:51pm EST

For personal use only

HEXIMA LIMITED

ASX ANNOUNCEMENT

02 November 2021

2021 ANNUAL GENERAL MEETING - CEO'S PRESENTATION

MELBOURNE, AUSTRALIA (2 December 2021): Hexima Limited (ASX:HXL) provides the attached CEO Presentation to be delivered at today's Annual General Meeting commencing at 11.00am AEDT.

The AGM can be joined at https://meetings.linkgroup.com/HXL21

This announcement is authorised for release to ASX by Michael Aldridge, Managing Director & CEO.

Enquiries:

Dr Nicole van der Weerden Chief Operating Officer n.vanderweerden@hexima.com.au

To join our email database and receive company announcements please click here

ABOUT HEXIMA

Hexima (ASX:HXL) is a clinical stage, anti-infectives focused biotechnology company engaged in the research and development of defensin peptides for applications as human therapeutics. Our lead product candidate, pezadeftide (HXP124) applied in a topical formulation, is a potential new prescription treatment for toenail fungal infections (or onychomycosis). Hexima is currently conducting an Australian phase IIb clinical trial testing pezadeftide for the treatment of onychomycosis. Hexima holds granted, long-life patents protecting pezadeftide in major markets globally. For additional information please visit www.hexima.com.au. You can also find us on Twitterand LinkedInor email us at info@hexima.com.au.

LEVEL 4 LIMS 2, KINGSBURY DRIVE, LA TROBE UNIVERSITY VIC 3086

1

ersonal use only

MANAGING DIRECTOR & CHIEF EXECUTIVE OFFICER PRESENTATION

MR MICHAEL ALDRIDGE

MAJOR ACHIEVEMENTS FY2021

onlyMilestones & Achievements

Public Offering and listing on ASX

use

o $3 million offering at A$0.20 per share

Phase IIb clinical trial

ersonal

o Initiation and completion of enrolment

Intellectual property protection

Scientific Advisory Board

o Australian, US and Japan KOLs

CompliancePak

AGM 2021

S L I D E 3

12 WEEK DAILY DOSING FOLLOWED
BY ONCE WEEKLY DOSING
ONCE-WEEKLYDOSING
WEEK
13

A U S T R A L I A N P H A S E I I B C L I N I C A L T R I A L

HXP124-ONY-002

Enrolment completed

only 12 WEEK

DAILY DOSING use

31 WEEK

DAILY DOSING

ersonalDAILY DOSING NOTE: DAILY DOSING PERIODS INCLUDE 1-WEEKWASHOUTS EVERY 6 WEEKS

HXP124-ONY-002 ANZCTR registration number: ACTRN12620000697987

WEEK

WEEK

WEEK

24

36

40

NO DOSING

FOLLOW-UP VISITS

WASHOUT PERIOD

AGM 2021

July 2021

  • Multi-center,randomised, double blind, vehicle-controlled study
  • Primary endpoint safety and tolerability, secondary endpoints Mycological Cure and Clinical Efficacy
  • Three active (2% pezadeftide) versus vehicle arms to test optimal dosing strategy
  • Safety & efficacy assessed at 13, 24, 36 and 40 weeks, data expected Q2 2022

SLID 4

E

S t r o n g p a t e n t p o s i t i o n

ADDITIONAL PROTECTION VIA FORMULATION PATENTS AND MARKET

only

EXCLUSIVITY FOR BIOLOGICS

Clearly defined

use

growth strategy

Develop independently in

US and EU (ICH) markets

License and collaborative

ersonal

development in Japan and potentially China - presently in preliminary discussions with multiple parties

Granted patents

Granted and

12-year US market

(exp 2035) in major

pending patents

exclusivity on FDA

markets covering the

covering stabilising

approval likely available

use of pezadeftide in

formulation for

as a biologic drug

the treatment of

pezadeftide

onychomycosis

AGM 2021

SLIDE 5

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

Hexima Limited published this content on 01 December 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 01 December 2021 22:50:05 UTC.


ę Publicnow 2021
All news about HEXIMA LIMITED
01/30Hexima Limited Declares Voting Results
CI
01/03Arovella Therapeutics Appoints COO
MT
2022Hexima Acting CEO to Step Down
MT
2022Nicole Van Der Weerden to Step Down as CEO of Hexima Limited
CI
2022Hexima Receives AU$6 Million Tax Incentive Refund from Australian Taxation Office
MT
2022Hexima Limited Receives Requisition Notice from Merchant Biotech Fund
CI
2022Hexima Limited Announces Board Changes
CI
202210,150,000 Options of Hexima Limited are subject to a Lock-Up Agreement Ending on 1-DEC..
CI
20226,925,878 Ordinary Shares of Hexima Limited are subject to a Lock-Up Agreement Ending o..
CI
2022Hexima : 2022 Annual Financial Report
PU
More news
Financials
Sales 2022 5,81 M 4,11 M 4,11 M
Net income 2022 -10,0 M -7,09 M -7,09 M
Net cash 2022 3,96 M 2,80 M 2,80 M
P/E ratio 2022 -0,46x
Yield 2022 -
Capitalization 2,84 M 2,01 M 2,01 M
EV / Sales 2021 4,62x
EV / Sales 2022 0,18x
Nbr of Employees -
Free-Float 51,4%
Chart HEXIMA LIMITED
Duration : Period :
Hexima Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers and Directors
Jonathan West Non-Executive Chairman
Marilyn Ann Anderson Chief Scientific Officer
Yolanda Gaspar Head-Clinical Operations
Scott Robertson Independent Non-Executive Director
Nicole Louise van der Weerden Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
HEXIMA LIMITED-15.00%2
MODERNA, INC.-2.96%66 963
IQVIA HOLDINGS INC.13.96%43 368
LONZA GROUP AG14.99%42 273
ALNYLAM PHARMACEUTICALS, INC.-4.73%27 670
SEAGEN INC.8.19%25 813